- Home
- RDNW vs SGMT Comparison
RDNW vs SGMT Comparison
Compare RDNW & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RDNW | SGMT |
|---|---|---|
| Founded | 2013 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 202.9M | 238.7M |
| IPO Year | N/A | 2023 |
Fundamental Metrics
Financial Performance| Metric | RDNW | SGMT |
|---|---|---|
| Price | $6.06 | $5.66 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 7 |
| Target Price | $4.00 | ★ $29.71 |
| AVG Volume (30 Days) | 51.9K | ★ 530.1K |
| Earning Date | 11-04-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,095,200,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $7.35 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.46 | $1.73 |
| 52 Week High | $6.58 | $11.41 |
Technical Indicators
Market Signals| Indicator | RDNW | SGMT |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 38.70 |
| Support Level | N/A | $5.43 |
| Resistance Level | N/A | $6.11 |
| Average True Range (ATR) | 0.00 | 0.29 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 0.00 | 21.84 |
Price Performance
Historical ComparisonAbout RDNW RideNow Group Inc.
RideNow Group Inc is a USA-based online retailer that allows consumers and dealers both to Buy-Sell-Trade-Finance pre-owned motorcycles in an efficient, fast, transparent, and engaging experience.
About SGMT Sagimet Biosciences Inc. Series A
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.